alovudine has been researched along with fluorodeoxyglucose f18 in 180 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 58 (32.22) | 29.6817 |
| 2010's | 112 (62.22) | 24.3611 |
| 2020's | 10 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Bares, R; Bartusek, G; Dittmann, H; Dohmen, BM; Kehlbach, R; Pritzkow, M; Sarbia, M | 1 |
| Arulampalam, TH; Costa, DC; Ell, PJ; Francis, DL; Luthra, SK; Taylor, I; Townsend, C; Visvikis, D | 1 |
| Aboagye, EO; Barthel, H; Brady, F; Cleij, MC; Collingridge, DR; He, Q; Hutchinson, OC; Luthra, SK; Osman, S; Price, PM | 1 |
| Bares, R; Dittmann, H; Dohmen, BM; Eichhorn, K; Eschmann, SM; Horger, M; Machulla, HJ; Paulsen, F; Wehrmann, M | 1 |
| Buck, AK; Glatting, G; Halter, G; Hetzel, M; Kotzerke, J; Mattfeldt, T; Neumaier, B; Reske, SN; Schirrmeister, H; Wurziger, I | 1 |
| Cobben, DC; Elsinga, PH; Hoekstra, HJ; Jager, PL; Maas, B; Suurmeijer, AJ; Vaalburg, W; van der Laan, BF | 1 |
| Bares, R; Dittmann, H; Dohmen, BM; Fersis, N; Machulla, HJ; Reischl, G; Smyczek-Gargya, B; Vogel, U; Wallwiener, D | 1 |
| Arulampalam, TH; Costa, DC; Croasdale, I; Ell, PJ; Francis, DL; Luthra, SK; Taylor, I; Visvikis, D | 1 |
| Cobben, DC; de Vries, EF; Elsinga, PH; Hoekstra, HJ; Jager, PL; Maas, B; Suurmeijer, AJ; Vaalburg, W; van Waarde, A | 1 |
| Chatal, JF; Couturier, O; Hustinx, R | 1 |
| Buck, AK; Glatting, G; Halter, G; Hetzel, M; Kratochwil, C; Mattfeldt, T; Möller, P; Mottaghy, FM; Neumaier, B; Reske, SN; Schirrmeister, H; Wahl, A | 1 |
| Barrio, J; Czernin, J; Halpern, BS; Mellinghoff, IK; Phelps, ME; Rozengurt, N; Safaei, A; Satyamurthy, N; Sawyers, CL; Silverman, DH; Stout, D; Tran, C; Waldherr, C; Weber, WA | 1 |
| Cobben, DC; Elsinga, PH; Jager, PL; Plukker, JT; van Dullemen, HM; van Westreenen, HL; Wesseling, J | 1 |
| Bergsneider, M; Chen, W; Cloughesy, T; Czernin, J; Kamdar, N; Liau, L; Mischel, P; Phelps, ME; Satyamurthy, N; Silverman, DH | 1 |
| Krohn, KA; Link, JM; Mankoff, DA; Muzi, M; Spence, AM | 1 |
| Chen, DL; Dehdashti, F | 1 |
| de Korte, MA; de Vries, EG; Jager, PL; Koopmans, KP; Lub-de Hooge, MN; Perik, PJ; van Waarde, A | 1 |
| Binns, D; Conus, N; Cullinane, C; Dorow, DS; Hicks, RJ; McArthur, GA; McCarthy, TJ; Roselt, P | 1 |
| Fujibayashi, Y; Furukawa, T; Kado, H; Kawai, H; Kubota, T; Nakagawa, T; Takamatsu, S; Toyohara, J; Yonekura, Y | 1 |
| Cameron, RB; Czernin, J; Fishbein, MC; Phelps, ME; Schiepers, C; Weber, WA; Yap, CS | 1 |
| Deisenhofer, S; Reske, SN | 1 |
| Charnley, N; Price, P; Saleem, A | 1 |
| Gault, N; Grahek, D; Gutman, F; Kerrou, K; Montravers, F; Schlienger, M; Talbot, JN; Touboul, E | 1 |
| Bommer, M; Buck, AK; Bunjes, D; Döhner, H; Glatting, G; Juweid, M; Krause, BJ; Mattfeldt, T; Möller, P; Mottaghy, FM; Neumaier, B; Reske, SN; Schirrmeister, H; Stilgenbauer, S; Tepsic, D | 1 |
| Liang, ZY; Liu, X; Zhang, JM; Zheng, X; Zhou, NK | 1 |
| Chao, KS | 2 |
| Becker, K; Geinitz, H; Lordick, F; Rosenberg, R; Rummeny, E; Schwaiger, M; Siewert, JR; Stahl, A; Stollfuss, J; Wieder, HA | 1 |
| Chang, ST; Gambhir, SS; Goodman, KA; Koong, AC; Loo, BW; McMillan, A; Patel, DA; Quon, A; Thorndyke, B | 1 |
| Been, LB; Elsinga, PH; Hoekstra, HJ; Jager, PL; Suurmeijer, AJ; van Ginkel, RJ | 1 |
| Egerer, G; Eisenhut, M; Gronkowski, M; Haberkorn, U; Haufe, S; Ho, AD; Kasper, B; Lehnert, T; Mechtersheimer, G | 1 |
| Nutt, R; Ridinger, MH; Vento, LJ | 1 |
| Bandoh, S; Chang, SS; Haba, R; Ishikawa, S; Kanaji, N; Kushida, Y; Nakano, J; Nishiyama, Y; Ohkawa, M; Yamamoto, Y | 1 |
| Ell, PJ; Groves, AM; Haim, SB; Win, T | 1 |
| Asakura, M; Bandoh, S; Ishikawa, S; Kanaji, N; Kimura, N; Nishiyama, Y; Ohkawa, M; Okuda, M; Yamamoto, Y | 1 |
| Vallabhajosula, S | 1 |
| Becker, K; Buck, AK; Herrmann, K; Krause, BJ; Lordick, F; Ott, K; Schuster, T; Schwaiger, M; Siewert, JR; Souvatzoglou, M; Wester, HJ; Wilhelm, D | 1 |
| Kanegae, K; Kohanawa, M; Kuge, Y; Seki, K; Takahashi, T; Tamaki, N; Yi, M; Zhao, S; Zhao, Y | 1 |
| Chen, P; Feng, H; Ma, L; Tan, Y; Tian, J; Wu, W; Xin, J; Yang, X; Yu, L; Zhao, Z | 1 |
| Angelberger, P; Becherer, A; Dudczak, R; Ewers, R; Kermer, C; Kletter, K; Linecker, A; Sulzbacher, I | 1 |
| Bandoh, S; Haba, R; Ishida, T; Kadota, K; Kanaji, N; Kohno, K; Kushida, Y; Matsunaga, T; Takano, K; Yamamoto, Y | 1 |
| Dence, CS; Lewis, JS; Ponde, DE; Welch, MJ | 1 |
| Haba, R; Hagiike, M; Izuishi, K; Kaji, M; Kameyama, R; Murota, M; Nishiyama, Y; Takebayashi, R; Yamamoto, Y | 1 |
| Fukumoto, D; Harada, N; Kakiuchi, T; Kamijo, A; Kawaguchi, AT; Murayama, C; Tsukada, H | 1 |
| Bussink, J; Kaanders, JH; Oyen, WJ; Troost, EG | 1 |
| Buck, AK; Dechow, T; Herrmann, K; Schwaiger, M; Shen, C; Wester, HJ | 1 |
| Emonds, KM; Mortelmans, L; Mottaghy, FM; Swinnen, JV | 1 |
| Ball, D; Binns, D; Everitt, S; Hicks, RJ; Kron, T; Mac Manus, M; Schneider-Kolsky, M; Walter, T | 1 |
| Benz, MR; Czernin, J; Eilber, FC; Federman, N; Tap, WD; Tchekmedyian, N | 1 |
| Brepoels, L; De Groot, T; De Wolf-Peeters, C; Mortelmans, L; Stroobants, S; Verhoef, G | 1 |
| Han, DL; Jiang, WR; Yu, JM | 1 |
| Ahn, SH; Cheon, GJ; Choi, CW; Chun, KS; Kang, JH; Lee, TS; Lim, SM; Moon, BS | 1 |
| Been, LB; Elsinga, PH; Hoekstra, HJ; Jager, PL; Suurmeijer, AJ; van der Laan, BF | 1 |
| De Weer, S; Debucquoy, A; Devos, E; Haustermans, K; Landuyt, W; Van Den Heuvel, F; Vermaelen, P | 1 |
| Boin, C; Bousquet, G; Cuvier, C; Espié, M; Giacchetti, S; Groheux, D; Hindié, E; Misset, JL; Moretti, JL; Teyton, P | 1 |
| Asakura, M; Haba, R; Hagiike, M; Izuishi, K; Kameyama, R; Nishiyama, Y; Takebayashi, R; Yamamoto, Y | 1 |
| Chen, Y; Li, T; Liu, J; Qu, B; Tian, J; Wang, H; Wang, S; Zhang, J | 1 |
| Fu, Z; Han, D; He, W; Huo, Z; Kong, L; Liu, X; Lu, J; Mu, D; Sun, X; Yin, Y; Yu, J; Yu, Y; Zhang, B; Zhang, G; Zhao, S; Zhong, X | 1 |
| Jackson, A; Trigonis, I | 1 |
| D'Souza, M; Datta, A; Garg, G; Grover, RK; Jaimini, A; Kumar, N; Mishra, AK; Mondal, A; Panwar, P; Sharma, R; Singh, D; Tripathi, M; Varshney, R | 1 |
| Allen-Auerbach, MS; Benz, MR; Chmielowski, B; Czernin, J; Gomez-Navarro, J; McCarthy, T; Radu, C; Ribas, A; Seja, E; Williams, JL | 1 |
| Cabrera, AR; Chen, L; Han, A; Han, D; Li, Y; Ma, L; Ma, Y; Mu, D; Sun, X; Teng, X; Yu, J; Yue, J; Zhao, S; Zhao, X; Zheng, F; Zheng, J | 1 |
| Fu, Z; Han, A; Mu, D; Sun, X; Yang, W; Yu, J; Zhang, Y | 1 |
| Gidding, CE; Gilles, R; Janssens, GO; Oyen, WJ; van der Vliet, TM; Vogel, WV | 1 |
| Weber, WA | 1 |
| Aide, N; Beauregard, JM; Cullinane, C; Dorow, D; Hicks, RJ; Kinross, K; Neels, O; Potdevin, T; Roselt, P | 1 |
| Aboagye, EO; Albarghach, NM; Cheze-Le Rest, C; Hatt, M; Kenny, LM; Metges, JP; Pradier, O; Rosso, L; Turkheimer, FE; Visvikis, D | 1 |
| Jeraj, R; Simoncic, U | 1 |
| Burkholder, I; Combs, SE; Essig, M; Giesel, FL; Haberkorn, U; Henze, M; Kauczor, HU; Kroll, A; Meissner, M; Stieltjes, B; Tüttenberg, J; Vogt-Schaden, M; Weber, MA; Zimmer, F; Zoubaa, S | 1 |
| Björkling, F; Erichsen, KD; Højgaard, L; Jensen, MM; Jensen, PB; Kjær, A; Madsen, J; Sehested, M | 1 |
| Chen, Y; Guan, Z; Liu, C; Shao, M; Tian, J; Wang, H; Wang, R; Xu, B; Yao, S; Yin, D; Zhang, J | 1 |
| Bohn, P; Dubray, B; Edet-Sanson, A; Gardin, I; Hapdey, S; Ménard, JF; Modzelewski, R; Salles, A; Thiberville, L; Vera, P | 1 |
| Billotey, C; Borson-Chazot, F; Bournaud, C; Cornu, C; Giammarile, F; Hervieu, V; Houzard, C; Janier, M; Le Bars, D; Lombard-Bohas, C; Masson, S; Scoazec, JY; Vuillez, JP; Walter, T | 1 |
| Boellaard, R; de Langen, AJ; Frings, V; Hoekstra, OS; Smit, EF; van Tinteren, H; van Velden, FH | 1 |
| Guleryuz, S; Manning, HC; Smith, RA | 1 |
| Binns, DS; Callahan, J; Conti, P; Fine, BM; Hicks, RJ; Macfarlane, D; Mileshkin, L; Pirzkall, A; Scott, AM; Yu, W | 1 |
| Banerjee, D; Bertino, JR; Blasberg, RG; Cai, S; de Stanchina, E; Kochetkov, T; Moroz, MA; Nair, J; Schwartz, GK; Serganova, I; Shamis, M; Wu, J | 1 |
| Aboagye, EO; Al-Nahhas, A; Kenny, LM | 1 |
| Baba, M; Fukumura, T; Inubushi, M; Koizumi, M; Miyamoto, T; Nakajima, M; Saga, T; Tanimoto, K; Yamamoto, N; Yoshikawa, K | 1 |
| Boellaard, R; Buettner, R; Dietlein, M; Draube, A; Engel-Riedel, W; Hallek, M; Hellmich, M; Heukamp, L; Jacobs, AH; Ko, YD; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Papachristou, I; Querings, S; Scheffler, M; Schlesinger, A; Schulte, K; Smit, E; Stoelben, E; Thomas, RK; Toepelt, K; Ullrich, RT; Wolf, J; Zander, T | 1 |
| Horky, LL; Treves, ST | 1 |
| Krause, BJ; Lordick, F; Ott, K | 1 |
| Bales, J; Duchamp, O; Gingles, N; Jacobs, V; Keen, H; Kukuk, D; Pichler, B; Raguin, O; Ricketts, SA; Shannon, A; Wedge, SR; Whalley, N | 1 |
| Arango, ME; Binns, D; Bogatyreva, E; Christensen, JG; Cullinane, C; Dorow, DS; Hicks, RJ; Jackson, S; McArthur, GA; Solomon, B; Young, R | 1 |
| Boellaard, R; Cheebsumon, P; de Langen, AJ; Frings, V; Hoekstra, OS; Lammertsma, AA; van Velden, FH; Yaqub, M | 1 |
| Calaminus, C; Duchamp, O; Honndorf, VS; Judenhofer, MS; Kukuk, D; Machulla, HJ; Pichler, BJ; Quintanilla-Martinez, L; Raguin, O; Reischl, G; Schönberger, T; Wiehr, S | 1 |
| Axente, M; Bass, CP; He, J; Hirsch, JI; Pugachev, A; Sundaresan, G; Zweit, J | 1 |
| Chang, CH; Chen, JT; Chen, LC; Ho, CL; Lee, TW; Lee, WC; Wang, YL; Wu, YH | 1 |
| Fu, Z; Han, D; Mu, D; Xu, G; Yang, W; Yu, J; Zhang, B; Zhao, S; Zhong, X | 1 |
| Boellaard, R; Dietlein, M; Holstein, A; Kahraman, D; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Scheffler, M; Ullrich, RT; Wolf, J; Zander, T | 2 |
| Buck, AK; Dechow, T; Graf, N; Herrmann, K; Keller, U; Peschel, C; Rudelius, M; Scheuerer, C; Schuster, T; Schwaiger, M; Wester, HJ | 1 |
| Bukofzer, G; Chakravartty, A; Cole, TB; Day, M; Donawho, CK; Fox, GB; Holich, KD; Luo, Y; Mudd, SR; Palma, JP; Reuter, DR; Tapang, P; Voorbach, MJ | 1 |
| Beer, AJ; Buck, AK; Dobritz, M; Erkan, M; Friess, H; Herrmann, K; Kleeff, J; Schmid, RM; Schuster, T; Schwaiger, M; Siveke, JT; Wester, HJ | 1 |
| Imai, Y; Kita, M; Senda, M; Takaoka, A; Yamane, T | 1 |
| Aboagye, EO; Gabra, H; Perumal, M; Stronach, EA | 1 |
| Hatakeyama, T; Kawai, N; Miyake, K; Okada, M; Shinomiya, A; Tamiya, T | 1 |
| Aridome, K; Jinguji, M; Kajiya, Y; Mori, S; Nakajo, M; Suenaga, T; Tanaka, S | 1 |
| Ayers, GD; Fluckiger, JU; Peterson, TE; Tantawy, MN; Whisenant, JG; Yankeelov, TE | 1 |
| Backes, H; Bjerkvig, R; Brekka, N; Hoehn, M; Jacobs, AH; Jikeli, JF; Miletic, H; Monfared, P; Neumaier, B; Niclou, SP; Stieber, D; Talasila, KM; Tavitian, B; Thorsen, F; Viel, T; Waerzeggers, Y; Wang, J; Winkeler, A | 1 |
| Civelek, AC; Huang, T; Jiang, H; Li, J; Li, XF; Ng, CK; Postel, GC; Shen, B | 1 |
| Buck, AK; Buck, D; Drzezga, A; Förschler, A; Hemmer, B; Korn, T; Krause, BJ; Lapa, C; Nessler, S; Schuster, T; Stadelmann, C; Vollmar, P; Wester, HJ; Zimmer, C | 1 |
| Hoshikawa, H; Kishino, T; Mori, N; Nishiyama, Y; Yamamoto, Y | 1 |
| Aichler, M; Baumgart, A; Buck, A; Dechow, T; Feuchtinger, A; Graf, N; Herrmann, K; Jünger, A; Keller, U; Li, Z; Peschel, C; Schwaiger, M; Walch, A | 1 |
| Boucher, KM; Butterfield, RI; Christian, PE; Enslow, MS; Heilbrun, ME; Hoffman, JM; Jensen, RL; Kadrmas, DJ; Morton, KA; Zollinger, LV | 1 |
| Akiyama, K; Hoshikawa, H; Inamoto, R; Kishino, T; Mori, N; Mori, T; Nishiyama, Y; Yamamoto, Y | 2 |
| Bhattacharya, A; Manohar, K; Mittal, BR; Radotra, BD; Verma, GR | 1 |
| Boellaard, R; Dietlein, M; Holstein, A; Kahraman, D; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Scheffler, M; Wolf, J; Zander, T | 1 |
| Aichler, M; Buck, AK; Dechow, T; Feuchtinger, A; Graf, N; Herrmann, K; Keller, U; Numberger, B; Peschel, C; Schuster, T; Schwaiger, M; Senekowitsch-Schmidtke, R; Wester, HJ; Zwisler, D | 1 |
| Hoffman, JM; Kadrmas, DJ; Rust, TC | 1 |
| Boellaard, R; Büttner, R; Dietlein, M; Engel-Riedel, W; Heukamp, L; Kahraman, D; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Papachristou, I; Querings, S; Scheffler, M; Stoelben, E; Wolf, J; Zander, T | 1 |
| Björkling, F; Bzorek, M; Erichsen, KD; Højgaard, L; Jensen, MM; Jensen, PB; Johnbeck, CB; Kjær, A; Madsen, J; Sehested, M | 1 |
| Burgess, TL; Coxon, A; Gambhir, SS; Glaus, C; Gobalakrishnan, S; Lewis, XZ; Radinsky, R; Rex, K; Silva, MD | 1 |
| Cintolo, JA; Pryma, DA; Tchou, J | 1 |
| Björkling, F; Erichsen, KD; Højgaard, L; Jensen, MM; Jensen, PB; Johnbeck, CB; Kjær, A; Madsen, J; Sehested, M | 1 |
| Guo, W; Hu, S; Li, J; Wang, C; Yao, Z; Zhang, Y; Zhou, M | 1 |
| Chen, Y; Liu, B; Qu, B; Tian, J; Wang, H; Xu, B; Zhang, J | 1 |
| Aridome, K; Fukukura, Y; Jinguji, M; Kajiya, Y; Koriyama, C; Nakajo, M; Nihara, T; Nishimata, N; Shimaoka, S; Tanaka, S; Tani, A | 1 |
| Cheng, MF; Liu, KL; Tien, YW; Tzen, KY; Wang, HP; Wu, YW; Yen, RF | 1 |
| Blanchet, EM; Chen, CC; Herscovitch, P; Martucci, V; Millo, C; Pacak, K | 1 |
| Bejot, R; Bhakoo, KK; Goggi, JL; Moonshi, SS | 1 |
| Aide, N; Berriolo-Riedinger, A; Blagosklonov, O; Brenot-Rossi, I; Bridji, B; Cachin, F; Caignon, JM; Chaumet-Riffaud, P; Collombier, L; Courbon, F; Devillers, A; Doyeux, K; Dubray, B; Fernandez, P; Gremillet, E; Houzard, C; Kolesnikov-Gauthier, H; Modzelewski, R; Olivier, P; Roux, J; Tessonnier, L; Thureau, S; Vera, P; Vervueren, L | 1 |
| Bowen, SR; Bradshaw, TJ; Forrest, LJ; Jallow, N; Jeraj, R | 1 |
| Binns, D; Bogatyreva, E; Bradley, DP; Cullinane, C; de Jong, R; Hicks, RJ; McArthur, GA; Waldeck, KL | 1 |
| Reichert, DE | 1 |
| Cheng, X; Navab, N; Shi, K; Ziegler, SI | 1 |
| Delcuratolo, M; Iftner, T; Kolb, A; Mantlik, F; Münch, P; Pichler, BJ; Probst, S; Schmidt, H; Stubenrauch, F; Wiehr, S | 1 |
| Fisker Hag, AM; Haagen Nielsen, C; Johnbeck, CB; Kjaer, A; Knigge, U; Munk Jensen, M | 1 |
| Boerman, OC; Fleuren, ED; Flucke, UE; Franssen, GM; Houghton, PJ; Oyen, WJ; Roeffen, MH; van der Graaf, WT; Versleijen-Jonkers, YM | 1 |
| Aboagye, EO; Faber, C; Griffiths, J; Heinzmann, K; Hermann, S; Honess, DJ; Jacobs, AH; Kopka, K; Kuhlmann, MT; Müller-Tidow, C; Schäfers, M; Schelhaas, S; Schneider, R; Schober, O; Smith, DM; Viel, T; Wachsmuth, L; Wagner, S | 1 |
| Ball, DL; Binns, D; Callahan, J; Collins, M; Everitt, SJ; Herschtal, A; Hicks, RJ; Kron, T; MacManus, M; Plumridge, N; Schneider, M | 1 |
| Ball, DL; Chabrot, M; Everitt, SJ; Hicks, RJ; Leimgruber, A; MacManus, M; Möller, A; Solomon, B | 1 |
| Armeanu-Ebinger, S; Fuchs, J; Griessinger, CM; Herrmann, D; Kneilling, M; Pichler, BJ; Seitz, G | 1 |
| Adler, S; Choyke, PL; Kurdziel, KA; Lindenberg, ML; Logan, J; Mena, E; Shih, J; Turkbey, BI; Wilson, W; Wong, K | 1 |
| An, H; Chen, H; Li, Y; Lin, Q; Sun, L; Wu, H; Zhao, L | 1 |
| Frechen, S; Fuhr, U; Kahraman, D; Kobe, C; Nogova, L; Scheffler, M; Suleiman, AA; Wolf, J; Zander, T | 1 |
| Balkay, L; Emri, M; Goda, K; Juhász, I; Krasznai, Z; Krasznai, ZT; Lajtos, I; Márián, T; Mikecz, P; Miklovicz, T; Németh, E; Szabó, G; Szalóki, G; Trencsényi, G | 1 |
| Berndorff, D; Chang, E; Cheng, Z; Ellinghaus, P; Gambhir, SS; Gekeler, V; Liu, H; Liu, S; Unterschemmann, K | 1 |
| Datz, L; Fastner, G; Hauser-Kronberger, C; Holzmannhofer, J; Öfner, D; Pirich, C; Rendl, G; Rettenbacher, L; Sedlmayer, F | 1 |
| Fukumura, T; Hoshikawa, H; Kishino, T; Mori, N; Mori, T; Nishiyama, Y; Samukawa, Y; Yamamoto, Y | 1 |
| Bhattacharya, A; Biswal, CK; Mittal, BR; Prabhakar, S; Shukla, J; Vatsa, R | 1 |
| Boellaard, R; Chamuleau, ME; Cillessen, SA; Hoekstra, OS; Hoetjes, N; Jauw, Y; Regelink, JC; Rizvi, SN; van de Ven, PM; Wondergem, MJ; Zijlstra, JM; Zweegman, S | 1 |
| Di Traglia, S; Galli, F; Lauri, C; Pizzichini, P; Signore, A | 1 |
| Bezak, E; Jennings, M; Marcu, LG | 1 |
| Carlson, ER; Heidel, RE; Schaefferkoetter, JD | 1 |
| Fujiwara, Y; Hamada, A; Hashimoto, J; Kanayama, Y; Kodaira, M; Kurihara, H; Miyakita, Y; Shimizu, C; Tamura, K; Tani, H; Watanabe, Y; Yamamoto, H; Yonemori, K; Yoshida, M; Yunokawa, M | 1 |
| Fu, Z; Hu, M; Li, C; Liu, J; Lu, J; Meng, X; Shi, X; Sun, X; Xing, L; Yu, J | 1 |
| Ai, H; Chen, S; Cheng, Z; Jiang, X; Li, X; Lu, H; Qing, H; Wei, R; Wu, C; Xu, G | 1 |
| Brekke, N; Fonnes, T; Haldorsen, IS; Kopperud, R; Krakstad, C; McCormack, E; Pavlin, T; Popa, M; Rygh, CB; Salvesen, HB; Visser, NC | 1 |
| Barjat, H; Emmas, SA; Honndorf, VS; Pichler, BJ; Quintanilla-Martinez, L; Schmidt, H; Stahlschmidt, A; Wehrl, HF; Wiehr, S | 1 |
| Agarwal, N; Beardmore, B; Boucher, K; Butterfield, RI; Hoffman, JM; Horn, KP; Kadrmas, DJ; Morton, KA; Yap, JT | 1 |
| Cao, J; Li, D; Ma, C; Yin, Y | 1 |
| Belanger, AP; Binderup, T; Calcagno, C; Courties, G; Di Carli, MF; Dubey, S; Fayad, ZA; Ishino, S; Iwamoto, Y; Johnbeck, CB; Keliher, EJ; Kjaer, A; Knigge, U; Libby, P; Mani, V; Mulder, WJ; Nahrendorf, M; Pérez-Medina, C; Swirski, FK; Tang, J; Tawakol, A; Weissleder, R; Wojtkiewicz, GR; Ye, YX | 1 |
| Dahlman, A; Fröhlich, C; Horak, ID; Jacobsen, HJ; Jensen, MM; Kjaer, A; Kragh, M; Kristensen, LK; Lantto, J; Nielsen, CH; Poulsen, TT | 1 |
| Agarwal, R; Bal, A; Dey, P; Gupta, D; Maturu, VN; Mittal, BR; Rayamajhi, SJ; Shukla, J | 1 |
| Andersson, M; Johansson, L; Leide-Svegborn, S; Mattsson, S; Minarik, D | 1 |
| Bencsikova, B; Kazda, T; Rehak, Z; Zambo, I | 1 |
| Boldt, K; Honndorf, VS; Kohlhofer, U; Kreft, L; Maurer, A; Pichler, BJ; Quintanilla-Martinez, L; Reischl, G; Rolle, AM; Schmidt, H; Schmitt, J; Schwarz, M; Wiehr, S | 1 |
| Jinguji, M; Kajiya, Y; Nakajo, M; Tani, A; Yoshiura, T | 1 |
| Berthelsen, AK; Binderup, T; Federspiel, B; Johnbeck, CB; Kjaer, A; Knigge, U; Langer, SW; Loft, A | 1 |
| Kuang, A; Ma, H; Pang, F; Ren, P; Shen, G | 1 |
| Jinguji, M; Kajiya, Y; Kitazono, M; Nakajo, M; Tani, A; Yoshiura, T | 1 |
| Nishiyama, Y; Noma, T; Norikane, T; Yamamoto, Y | 1 |
| Acevedo, M; Donovan, M; Huang, J; Leonard Watkins, G; Mundt, C; Ponto, LLB; Sunderland, J; Thede-Reynolds, K; Walsh, S | 1 |
| Jiang, HJ; Li, M; Li, X; Pan, WB; Wang, YQ; Xu, HL; Zhang, MY; Zhang, RJ | 1 |
| Cegla, P; Joanna, K; Julian, M; Michal, S; Sebastian, G; Witold, C | 1 |
| Anton-Rodriguez, JM; Coope, D; Djoukhadar, I; Evans, DG; Jackson, A; Julyan, P; King, AT; Lewis, D; Lloyd, SKL; Matthews, JC; Russell, D | 1 |
| Broccoli, A; Fanti, S; Fonti, C; Lambertini, A; Lodi, F; Nanni, C; Pellegrini, C; Stefoni, V; Zanoni, L; Zinzani, PL | 1 |
| Chmielowska, E; Kuliczkowski, K; Małkowski, B; Olejniczak, M; Rybka, J; Sokołowska, E; Wróbel, T | 1 |
| Mitamura, K; Nishiyama, Y; Norikane, T; Tani, R; Yamamoto, Y | 1 |
| Bak, B; Cegła, P; Cholewinski, W; Kazmierska, J; Malicki, J; Piotrowski, T; Sowinska, A | 1 |
| Calderoni, L; Castellucci, P; Fanti, S; Telo, S; Vichi, S; Zagni, F | 1 |
| Fujimoto, K; Mitamura, K; Nishiyama, Y; Norikane, T; Takami, Y; Yamamoto, Y | 1 |
| Fujimoto, K; Mitamura, K; Nishiyama, Y; Norikane, T; Okano, K; Suzuki, Y; Yamamoto, Y | 1 |
| Nishiyama, Y; Norikane, T | 1 |
| Chan, SC; Chang, PH; Hsieh, JC; Huang, JS; Lui, KW; Ng, SH; Su, TP | 1 |
| Byrd, DW; Doot, RK; Kinahan, PE; Krohn, KA; Kurland, BF; Linden, HM; Link, JM; Mankoff, DA; Muzi, M; Novakova-Jiresova, A; Peterson, LM; Romine, PE; Specht, JM | 1 |
| Kuge, Y; Matsuda, T; Nakajima, K; Ogawa, M; Suzuki, M; Yokouchi, Y | 1 |
| Bando, Y; Ikushima, H; Kondo, K; Kuwahara, K; Miyoshi, H; Otani, T; Otsuka, H; Yamashita, M | 1 |
23 review(s) available for alovudine and fluorodeoxyglucose f18
| Article | Year |
|---|---|
[Fluorinated analogs of nucleosides and fluorinated tracers of gene expression for positron emission tomography].
Topics: Animals; Antiviral Agents; Dideoxynucleosides; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Ganciclovir; Genes, Reporter; Genetic Therapy; Guanine; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Simplexvirus | 2004 |
True tracers: comparing FDG with glucose and FLT with thymidine.
Topics: Animals; Brain; Brain Mapping; Brain Neoplasms; Dideoxynucleosides; Fluorodeoxyglucose F18; Glucose; Humans; Image Interpretation, Computer-Assisted; Radionuclide Imaging; Radiopharmaceuticals; Thymidine | 2005 |
Advances in positron emission tomographic imaging of lung cancer.
Topics: Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Hypoxia; Lung Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2005 |
Molecular imaging: what can be used today.
Topics: Animals; Biochemical Phenomena; Biomarkers, Tumor; Diagnostic Imaging; Dideoxynucleosides; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Medical Oncology; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, ErbB-2; Receptors, Cell Surface | 2005 |
Clinical molecular imaging with positron emission tomography.
Topics: Antineoplastic Agents; Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals | 2006 |
[PET and malignant cerebral tumors].
Topics: Brain Neoplasms; Choline; Dideoxynucleosides; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Glioma; Humans; Methionine; Positron-Emission Tomography; Radiopharmaceuticals | 2006 |
Functional imaging for early prediction of response to chemoradiotherapy: 3'-deoxy-3'-18F-fluorothymidine positron emission tomography--a clinical application model of esophageal cancer.
Topics: Combined Modality Therapy; Dideoxynucleosides; Esophageal Neoplasms; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Positron-Emission Tomography | 2006 |
Non-[18F]FDG PET in clinical oncology.
Topics: Antibodies; Choline; Dideoxynucleosides; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Medical Oncology; Neoplasms; Oxygen; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Estrogen; Receptors, Somatostatin | 2007 |
(18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
Topics: Amino Acids; Animals; Bone and Bones; Cell Hypoxia; Choline; Dideoxynucleosides; Dihydroxyphenylalanine; Estradiol; Fluorine Radioisotopes; Fluoroacetates; Fluorodeoxyglucose F18; Glucose; Humans; Membrane Lipids; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2007 |
Molecular imaging of prostate cancer.
Topics: Animals; Antigens, Neoplasm; Bombesin; Cell Line, Tumor; Choline; Dideoxynucleosides; Dihydrotestosterone; Fluorodeoxyglucose F18; GPI-Linked Proteins; Humans; Male; Membrane Glycoproteins; Molecular Diagnostic Techniques; Neoplasm Proteins; Positron-Emission Tomography; Prostate; Prostatic Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon | 2009 |
Utilization of positron emission tomography in the management of patients with sarcoma.
Topics: Bone Neoplasms; Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Osteosarcoma; Positron-Emission Tomography; Radiopharmaceuticals; Sarcoma | 2009 |
[Application and future prospect of 18F-FLT PET-CT in guiding delineation of biological target volume].
Topics: Dideoxynucleosides; False Positive Reactions; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Inflammation; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiotherapy, Intensity-Modulated; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
[PET/CT in breast cancer: an update].
Topics: Breast Neoplasms; Carcinoma, Ductal, Breast; Dideoxynucleosides; Estradiol; Female; Fluorodeoxyglucose F18; Humans; Lymph Node Excision; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Sodium Fluoride; Treatment Outcome | 2009 |
Imaging pharmacodynamics in oncology: the potential significance of "flares".
Topics: Animals; Biological Transport; Diagnostic Imaging; Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Neoplasms; Pharmacokinetics; Radioactive Tracers | 2010 |
Molecular imaging metrics to evaluate response to preclinical therapeutic regimens.
Topics: Diagnostic Imaging; Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Molecular Imaging; Neoplasms; Neovascularization, Pathologic; Positron-Emission Tomography; Thymidine Kinase | 2011 |
PET and SPECT in brain tumors and epilepsy.
Topics: Brain; Brain Neoplasms; Cell Proliferation; Dideoxynucleosides; Epilepsy; Flumazenil; Fluorodeoxyglucose F18; GABA Modulators; Humans; Necrosis; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon | 2011 |
[Positron emission tomography - current role in the diagnosis and treatment of upper gastrointestinal carcinomas].
Topics: Adenocarcinoma; Combined Modality Therapy; Dideoxynucleosides; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Sensitivity and Specificity; Stomach Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Diagnostic and prognostic application of positron emission tomography in breast imaging: emerging uses and the role of PET in monitoring treatment response.
Topics: Breast Neoplasms; Clinical Trials as Topic; Dideoxynucleosides; Early Detection of Cancer; Estradiol; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Treatment Outcome | 2013 |
Current status of PET imaging of differentiated thyroid cancer with second generation radiopharmaceuticals.
Topics: Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Image Enhancement; Iodine Radioisotopes; Methionine; Radionuclide Imaging; Radiopharmaceuticals; Thyroid Neoplasms; Whole Body Imaging | 2015 |
PET-specific parameters and radiotracers in theoretical tumour modelling.
Topics: Cell Proliferation; Coordination Complexes; Dideoxynucleosides; Diffusion; Fluorodeoxyglucose F18; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glucose; Humans; Hydrogen-Ion Concentration; Hypoxia; Misonidazole; Models, Theoretical; Multimodal Imaging; Neoplasms; Neovascularization, Pathologic; Organometallic Compounds; Oxygen; Positron-Emission Tomography; Radiopharmaceuticals; Thiosemicarbazones; Tomography, X-Ray Computed | 2015 |
Molecular imaging using PET for breast cancer.
Topics: Bevacizumab; Breast Neoplasms; Carcinoma, Ductal, Breast; Cetuximab; Dideoxynucleosides; ErbB Receptors; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Molecular Imaging; Norprogesterones; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, Progesterone; Receptors, Vascular Endothelial Growth Factor; Trastuzumab | 2016 |
Correlations of 18F-FDG and 18F-FLT uptake on PET with Ki-67 expression in patients with lung cancer: a meta-analysis.
Topics: Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Ki-67 Antigen; Lung Neoplasms; Positron-Emission Tomography; Sensitivity and Specificity | 2018 |
Alternative and New Radiopharmaceutical Agents for Lung Cancer.
Topics: Acetates; Carbon Radioisotopes; Dideoxynucleosides; Fluorodeoxyglucose F18; Gallium Isotopes; Gallium Radioisotopes; Humans; Lung Neoplasms; Methionine; Misonidazole; Neoplasm Staging; Neuroendocrine Tumors; Peptides; Peptides, Cyclic; Positron Emission Tomography Computed Tomography; Quinolines; Radiopharmaceuticals; Sensitivity and Specificity | 2020 |
33 trial(s) available for alovudine and fluorodeoxyglucose f18
| Article | Year |
|---|---|
Potential impact of [18F]3'-deoxy-3'-fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer.
Topics: Aged; Aged, 80 and over; Colorectal Neoplasms; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed; Whole-Body Counting | 2003 |
[18F]FLT PET for diagnosis and staging of thoracic tumours.
Topics: Adult; Aged; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms, Unknown Primary; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Thoracic Neoplasms; Tomography, Emission-Computed | 2003 |
Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.
Topics: Adult; Aged; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Solitary Pulmonary Nodule; Statistics as Topic; Tomography, Emission-Computed | 2003 |
PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study.
Topics: Adult; Aged; Breast Neoplasms; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Middle Aged; Pilot Projects; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2004 |
Clinical relevance of imaging proliferative activity in lung nodules.
Topics: Adult; Aged; Aged, 80 and over; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Severity of Illness Index; Solitary Pulmonary Nodule | 2005 |
Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer.
Topics: Aged; Dideoxynucleosides; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2005 |
Impact of integrated PET/CT on variability of target volume delineation in rectal cancer.
Topics: Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Radiotherapy Planning, Computer-Assisted; Rectal Neoplasms; Tomography, X-Ray Computed | 2007 |
Detection of colorectal cancer using ¹⁸F-FLT PET: comparison with ¹⁸F-FDG PET.
Topics: Adult; Aged; Aged, 80 and over; Cell Proliferation; Colorectal Neoplasms; Dideoxynucleosides; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies | 2009 |
Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Cell Proliferation; CTLA-4 Antigen; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Spleen; Tomography, X-Ray Computed; Tumor Burden | 2010 |
Measuring tumor cell proliferation with 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study.
Topics: Aged; Aged, 80 and over; Bone Marrow Cells; Carcinoma, Squamous Cell; Cell Proliferation; Diagnosis, Differential; Dideoxynucleosides; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Inflammation; Lymphatic Metastasis; Male; Middle Aged; Neoplasm, Residual; Pilot Projects; Positron-Emission Tomography; Tomography, X-Ray Computed | 2010 |
Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Biological Transport; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cyclin D1; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Tomography, X-Ray Computed | 2010 |
Can multimodality imaging using 18F-FDG/18F-FLT PET/CT benefit the diagnosis and management of patients with pulmonary lesions?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Lung Diseases; Male; Middle Aged; Positron-Emission Tomography; Tomography, X-Ray Computed; Young Adult | 2011 |
18F-FLT and 18F-FDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumours.
Topics: Adult; Aged; Cell Differentiation; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Intestinal Neoplasms; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Stomach Neoplasms | 2011 |
Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer.
Topics: Biological Transport; Blood Glucose; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Erlotinib Hydrochloride; Feasibility Studies; Fluorodeoxyglucose F18; Guideline Adherence; Humans; Internationality; Lung Neoplasms; Positron-Emission Tomography; Quality Control; Quinazolines; Treatment Outcome | 2011 |
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Positron-Emission Tomography; Prognosis; Quinazolines | 2011 |
Comparison of the diagnostic value of 3-deoxy-3-18F-fluorothymidine and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of regional lymph node in thoracic esophageal squamous cell carcinoma: a pilot study.
Topics: Aged; Carcinoma, Squamous Cell; Dideoxynucleosides; Esophageal Neoplasms; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Pilot Projects; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2012 |
Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Topics: Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Staging; Positron-Emission Tomography; Quinazolines; Time Factors; Treatment Outcome | 2011 |
A pilot study to evaluate 3'-deoxy-3'-18F-fluorothymidine pet for initial and early response imaging in mantle cell lymphoma.
Topics: Aged; Aged, 80 and over; Biological Transport; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Lymphoma, Mantle-Cell; Male; Middle Aged; Pilot Projects; Positron-Emission Tomography; Prognosis; Time Factors; Treatment Outcome | 2011 |
18F-FLT PET performs better than 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma.
Topics: Adult; Aged; Biological Transport; Cell Proliferation; Diagnosis, Differential; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Leiomyoma; Middle Aged; Positron-Emission Tomography; Uterine Neoplasms | 2012 |
Comparison of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma.
Topics: Adult; Aged; Diagnosis, Differential; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Glioma; Humans; Male; Middle Aged; Necrosis; Neoplasm Grading; Positron-Emission Tomography; Radiation Injuries; Recurrence; Young Adult | 2012 |
Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dideoxynucleosides; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Quinazolines; Treatment Outcome | 2012 |
Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
Changes in (18)F-fluorothymidine and (18)F-fluorodeoxyglucose positron emission tomography imaging in patients with head and neck cancer treated with chemoradiotherapy.
Topics: Aged; Aged, 80 and over; Chemoradiotherapy; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2013 |
Usefulness of PET/CT for the differentiation and characterization of periampullary lesions.
Topics: Adult; Aged; Aged, 80 and over; Ampulla of Vater; Common Bile Duct Neoplasms; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Tomography, X-Ray Computed | 2013 |
Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
Topics: Adult; Aged; Algorithms; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Misonidazole; Observer Variation; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tumor Burden | 2013 |
Effect of Platinum-Based Chemoradiotherapy on Cellular Proliferation in Bone Marrow and Spleen, Estimated by (18)F-FLT PET/CT in Patients with Locally Advanced Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow Cells; Carcinoma, Non-Small-Cell Lung; Cell Count; Cell Proliferation; Chemoradiotherapy; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Male; Middle Aged; Neutrophils; Organ Specificity; Platinum; Positron-Emission Tomography; Spleen; Tomography, X-Ray Computed | 2014 |
Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Dideoxynucleosides; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Survival Analysis | 2015 |
18F-FDG or 3'-deoxy-3'-18F-fluorothymidine to detect transformation of follicular lymphoma.
Topics: Adult; Aged; Area Under Curve; Biomarkers, Tumor; Biopsy; Cell Transformation, Neoplastic; Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphoma, Follicular; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Prospective Studies; Remission Induction; ROC Curve; Sensitivity and Specificity; Tomography, X-Ray Computed | 2015 |
FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Dideoxynucleosides; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Indoles; Kidney Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Pyrroles; Radiopharmaceuticals; Sunitinib; Treatment Outcome | 2015 |
Comparison of characteristics of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET during staging of esophageal squamous cell carcinoma.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Dideoxynucleosides; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography | 2015 |
(18)F-FDG and (18)F-FLT PET/CT imaging in the characterization of mediastinal lymph nodes.
Topics: Adult; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Lymphadenopathy; Male; Mediastinum; Middle Aged; Positron Emission Tomography Computed Tomography; Prospective Studies; Young Adult | 2016 |
Prognostic Value of 18F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with 18F-FDG PET and Ki-67 in 100 Patients.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Dideoxynucleosides; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Ki-67 Antigen; Male; Middle Aged; Neuroendocrine Tumors; Positron-Emission Tomography | 2016 |
Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial.
Topics: Adult; Aged; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Sensitivity and Specificity | 2019 |
124 other study(ies) available for alovudine and fluorodeoxyglucose f18
| Article | Year |
|---|---|
Early changes in [18F]FLT uptake after chemotherapy: an experimental study.
Topics: Antineoplastic Agents; Artifacts; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; Deoxycytidine; Dideoxynucleosides; Dose-Response Relationship, Drug; Esophageal Neoplasms; Fluorodeoxyglucose F18; Fluorouracil; Gemcitabine; Humans; Methotrexate; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic; Tumor Cells, Cultured | 2002 |
3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
Topics: Adenosine Triphosphate; Animals; Dideoxynucleosides; Drug Monitoring; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; Humans; Mice; Mice, Inbred C3H; Mice, Nude; Neoplasms; Neoplasms, Experimental; Radiopharmaceuticals; Tissue Distribution; Tomography, Emission-Computed; Transplantation, Heterologous | 2003 |
18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET.
Topics: Aged; Biopsy; Carcinoma, Squamous Cell; Dideoxynucleosides; Feasibility Studies; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Laryngeal Neoplasms; Larynx; Male; Neoplasm Recurrence, Local; Prospective Studies; Radiopharmaceuticals; Tomography, Emission-Computed | 2004 |
Assessment of recurrent colorectal cancer following 5-fluorouracil chemotherapy using both 18FDG and 18FLT PET.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Dideoxynucleosides; Fluorodeoxyglucose F18; Fluorouracil; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Treatment Outcome | 2004 |
Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model.
Topics: Animals; Diagnosis, Differential; Dideoxynucleosides; Disease Models, Animal; Fluorodeoxyglucose F18; Glioma; Inflammation; Male; Metabolic Clearance Rate; Organ Specificity; Radionuclide Imaging; Radiopharmaceuticals; Rats; Rats, Wistar; Reproducibility of Results; Rodentia; Sensitivity and Specificity; Tissue Distribution; Turpentine | 2004 |
Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Disease Models, Animal; Fluorodeoxyglucose F18; Humans; Mice; Mice, SCID; Neoplasm Invasiveness; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Radiopharmaceuticals; Treatment Outcome | 2005 |
Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Topics: Adult; Aged; Brain Neoplasms; Cell Proliferation; Dideoxynucleosides; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glioma; Humans; Ki-67 Antigen; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Survival Rate | 2005 |
Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Dideoxynucleosides; ErbB Receptors; Fluorodeoxyglucose F18; Humans; Mice; Morpholines; Positron-Emission Tomography; Prognosis; Protein-Tyrosine Kinases; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome; Tumor Cells, Cultured | 2006 |
Acquisition of resistance to antitumor alkylating agent ACNU: a possible target of positron emission tomography monitoring.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Resistance, Neoplasm; Fluorodeoxyglucose F18; Glioma; Nimustine; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Rats; Treatment Outcome | 2006 |
Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Ki-67 Antigen; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Thoracic Neoplasms | 2006 |
Is 3'-deoxy-3'-(18)F-fluorothymidine a better marker for tumour response than (18)F-fluorodeoxyglucose?
Topics: Animals; Antineoplastic Agents; Dideoxynucleosides; Disease Models, Animal; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Mice; Neoplasms; Radionuclide Imaging; Reproducibility of Results | 2006 |
Molecular imaging of proliferation in malignant lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Cell Growth Processes; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Lymphoma; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Tissue Distribution | 2006 |
[Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dideoxynucleosides; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Lung Neoplasms; Male; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Positron-Emission Tomography; Proliferating Cell Nuclear Antigen; Tissue Distribution; Xenograft Model Antitumor Assays | 2006 |
PET imaging with [18F]3'-deoxy-3'-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer.
Topics: Adult; Aged; Cell Proliferation; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Rectal Neoplasms; Treatment Outcome | 2007 |
18F-fluorodeoxythymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas.
Topics: Adult; Aged; Dideoxynucleosides; Extremities; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Hypothermia, Induced; Male; Middle Aged; Positron-Emission Tomography; Sarcoma | 2007 |
3'-deoxy-3'-(18)F-fluorothymidine (FLT) positron emission tomography for early prediction of response to chemoradiotherapy--a clinical application model of esophageal cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Disease Models, Animal; Docetaxel; Esophageal Neoplasms; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Forecasting; Humans; Mice; Neoadjuvant Therapy; Neoplasm, Residual; Positron-Emission Tomography; Radiotherapy, Adjuvant; Remission Induction; Taxoids; Treatment Outcome | 2007 |
Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET.
Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Dideoxynucleosides; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lymphoma; Male; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals | 2007 |
In vivo molecular imaging biomarkers: clinical pharmacology's new "PET"?
Topics: Dideoxynucleosides; Drug Approval; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Misonidazole; Molecular Structure; Nitriles; Pharmacology, Clinical; Positron-Emission Tomography; Radioisotopes; Radiopharmaceuticals; United States; United States Food and Drug Administration | 2007 |
Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Ki-67 Antigen; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic | 2007 |
Comparison of (18)F-FLT PET and (18)F-FDG PET for preoperative staging in non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Preoperative Care; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2008 |
Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis.
Topics: Adult; Aged; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Pilot Projects; Radionuclide Imaging; Radiopharmaceuticals; Stomach Neoplasms; Tissue Distribution | 2007 |
Usefulness of 11C-methionine for differentiating tumors from granulomas in experimental rat models: a comparison with 18F-FDG and 18F-FLT.
Topics: Animals; Carbon Radioisotopes; Carcinoma, Hepatocellular; Cell Line, Tumor; Diagnosis, Differential; Dideoxynucleosides; Fluorodeoxyglucose F18; Granuloma; Inflammation; Liver Neoplasms; Male; Methionine; Mycobacterium bovis; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Turpentine | 2008 |
A multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 3'-deoxy-3'-18F-fluorothymidine and 18F-FDG.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; China; Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Solitary Pulmonary Nodule; Subtraction Technique; Tomography, X-Ray Computed | 2008 |
Uptake of (18)F-FLT and (18)F-FDG in primary head and neck cancer correlates with survival.
Topics: Adult; Aged; Aged, 80 and over; Dideoxynucleosides; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Immunohistochemistry; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Prospective Studies; Radioisotopes; Survival Analysis | 2008 |
Positron emission tomography-positive squalene-induced lipoid pneumonia confirmed by gas chromatography-mass spectrometry of bronchoalveolar lavage fluid.
Topics: Aged; Bronchoalveolar Lavage Fluid; Dideoxynucleosides; Fluorodeoxyglucose F18; Gas Chromatography-Mass Spectrometry; Humans; Male; Pneumonia, Lipid; Positron-Emission Tomography; Squalene | 2008 |
Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.
Topics: Animals; Autoradiography; Cell Line, Tumor; Coordination Complexes; Copper Radioisotopes; Dideoxynucleosides; Disease Models, Animal; Female; Fluorodeoxyglucose F18; Gliosarcoma; Humans; Metabolic Clearance Rate; Misonidazole; Organometallic Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Rats, Inbred F344; Thiosemicarbazones; Tissue Distribution | 2008 |
Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Cell Proliferation; Dideoxynucleosides; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Ki-67 Antigen; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Stomach Neoplasms | 2009 |
Evaluation of D-18F-FMT, 18F-FDG, L-11C-MET, and 18F-FLT for monitoring the response of tumors to radiotherapy in mice.
Topics: Animals; Carbon Radioisotopes; Carcinoma, Squamous Cell; Cell Line, Tumor; Dideoxynucleosides; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Methionine; Mice; Mice, Inbred C3H; Neoplasms, Experimental; Positron-Emission Tomography; Tyrosine | 2009 |
18F-FDG and 18F-FLT do not discriminate between reactive and metastatic lymph nodes in oral cancer.
Topics: Dideoxynucleosides; Excitatory Amino Acid Transporter 2; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Mouth Neoplasms; Radionuclide Imaging; Radiopharmaceuticals | 2009 |
Molecular imaging of proliferation in vivo: positron emission tomography with [18F]fluorothymidine.
Topics: Animals; Cell Proliferation; Clinical Trials as Topic; Diagnosis, Differential; Dideoxynucleosides; Disease Models, Animal; Fluorodeoxyglucose F18; Humans; Molecular Diagnostic Techniques; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2009 |
Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Combined Modality Therapy; Dideoxynucleosides; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2009 |
(18)F-FDG and (18)F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cyclophosphamide; Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Lymphoma; Metabolic Clearance Rate; Mice; Mice, SCID; Protein Kinase Inhibitors; Protein Kinases; Radionuclide Imaging; Radiopharmaceuticals; Sirolimus; Tissue Distribution; TOR Serine-Threonine Kinases; Treatment Outcome | 2009 |
Comparison of 18F-FDG, 18F-FET and 18F-FLT for differentiation between tumor and inflammation in rats.
Topics: Animals; Diagnosis, Differential; Dideoxynucleosides; Feasibility Studies; Female; Fluorodeoxyglucose F18; Inflammation; Neoplasms; Positron-Emission Tomography; Rats; Thymidine Phosphorylase; Tissue Distribution; Tyrosine | 2009 |
[18F]FLT-PET and [18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer.
Topics: Aged; Aged, 80 and over; Dideoxynucleosides; Feasibility Studies; Fluorodeoxyglucose F18; Humans; Laryngeal Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity | 2009 |
18F-FLT and 18F-FDG PET to measure response to radiotherapy combined with celecoxib in two colorectal xenograft models.
Topics: Animals; Celecoxib; Cell Line, Tumor; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Mice; Positron-Emission Tomography; Pyrazoles; Sulfonamides; Treatment Outcome; Xenograft Model Antitumor Assays | 2009 |
Using dual-tracer PET to predict the biologic behavior of human colorectal cancer.
Topics: Animals; Biological Transport; Blotting, Western; Cell Line, Tumor; Colorectal Neoplasms; Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Linear Models; Male; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Positron-Emission Tomography; Radioactive Tracers; Tomography, X-Ray Computed | 2009 |
Comparison of (18)F-fluorothymidine and (18)F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus.
Topics: Carcinoma, Squamous Cell; Dideoxynucleosides; Dose Fractionation, Radiation; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Heart; Humans; Lung; Lymph Node Excision; Male; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Spinal Cord; Tomography, X-Ray Computed; Tumor Burden | 2010 |
Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas.
Topics: Adolescent; Adult; Brain Neoplasms; Child; Child, Preschool; Dideoxynucleosides; Dihydroxyphenylalanine; Female; Fluorodeoxyglucose F18; Glioma; Humans; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Tomography, X-Ray Computed; Young Adult | 2009 |
(18)F-fluoro-L-thymidine-PET for the evaluation of primary brain tumours in children: a report of three cases.
Topics: Adolescent; Brain Neoplasms; Child, Preschool; Diagnosis, Differential; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Infant; Magnetic Resonance Imaging; Male; Positron-Emission Tomography | 2010 |
Monitoring tumor response to therapy with 18F-FLT PET.
Topics: Animals; Cell Proliferation; Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Neoplasms, Germ Cell and Embryonal; Neoplastic Processes; Positron-Emission Tomography; Treatment Outcome | 2010 |
A dual radiologic contrast agent protocol for 18F-FDG and 18F-FLT PET/CT imaging of mice bearing abdominal tumors.
Topics: Abdominal Neoplasms; Animals; Ascites; Contrast Media; Dideoxynucleosides; Fluorodeoxyglucose F18; Injections, Intravenous; Mice; Positron-Emission Tomography; Tomography, X-Ray Computed | 2011 |
Reproducibility of 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET tumor volume measurements.
Topics: Algorithms; Breast Neoplasms; Dideoxynucleosides; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Positron-Emission Tomography; Reproducibility of Results; Tumor Burden | 2010 |
Cumulative input function method for linear compartmental models and spectral analysis in PET.
Topics: Algorithms; Corpus Striatum; Dideoxynucleosides; Dopamine Agonists; Fluorodeoxyglucose F18; Humans; Kinetics; Linear Models; Models, Anatomic; Positron-Emission Tomography; Raclopride; Radiopharmaceuticals; Stimulation, Chemical | 2011 |
Biopsy targeting gliomas: do functional imaging techniques identify similar target areas?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspartic Acid; Biopsy; Brain Neoplasms; Choline; Contrast Media; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Gadolinium DTPA; Glioma; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Microcirculation; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Positron-Emission Tomography; Radiopharmaceuticals; Spin Labels; Stereotaxic Techniques | 2010 |
Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Dideoxynucleosides; Disease Models, Animal; Drug Monitoring; Female; Fluorodeoxyglucose F18; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Xenograft Model Antitumor Assays | 2010 |
Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients wit
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Misonidazole; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2011 |
Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Phantoms, Imaging; Prospective Studies; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results | 2010 |
Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Dideoxynucleosides; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; HCT116 Cells; Humans; Immunoblotting; Ki-67 Antigen; Methotrexate; Mice; Mice, Nude; Organophosphates; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Thymidine; Thymidine Kinase; Xenograft Model Antitumor Assays | 2011 |
Novel PET biomarkers for breast cancer imaging.
Topics: Biomarkers, Tumor; Breast Neoplasms; Dideoxynucleosides; Estradiol; Female; Fluorodeoxyglucose F18; Humans; Methionine; Positron-Emission Tomography | 2011 |
PET/CT with 3'-deoxy-3'-[18F]fluorothymidine for lung cancer patients receiving carbon-ion radiotherapy.
Topics: Aged; Aged, 80 and over; Carbon; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals | 2011 |
An evaluation of 2-deoxy-2-[18F]fluoro-D-glucose and 3'-deoxy-3'-[18F]-fluorothymidine uptake in human tumor xenograft models.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Histocytochemistry; Humans; Mice; Mice, Nude; Neoplasms, Experimental; Positron-Emission Tomography; Research Design; Transplantation, Heterologous; Whole Body Imaging | 2012 |
Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.
Topics: Animals; Biomarkers; Cell Line, Tumor; Cell Proliferation; Crizotinib; Dideoxynucleosides; Disease Models, Animal; Fluorodeoxyglucose F18; Glucose; Glucose Transporter Type 1; Humans; Mice; Mice, Inbred BALB C; Mice, SCID; Neoplasm Transplantation; Piperidines; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Signal Transduction | 2011 |
Effects of image characteristics on performance of tumor delineation methods: a test-retest assessment.
Topics: Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2011 |
Assessment of PET tracer uptake in hormone-independent and hormone-dependent xenograft prostate cancer mouse models.
Topics: Animals; Carbon Radioisotopes; Cell Line, Tumor; Choline; Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Male; Mice; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Orchiectomy; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Transplantation, Heterologous | 2011 |
Comprehensive approach to coregistration of autoradiography and microscopy images acquired from a set of sequential tissue sections.
Topics: Animals; Autoradiography; Carbon Radioisotopes; Cell Line, Tumor; Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Neoplasms, Experimental; Positron-Emission Tomography; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Transplantation, Heterologous; Tumor Microenvironment | 2011 |
Early detection of tumor response by FLT/microPET Imaging in a C26 murine colon carcinoma solid tumor animal model.
Topics: Animals; Antibiotics, Antineoplastic; Colonic Neoplasms; Dideoxynucleosides; Doxorubicin; Fluorodeoxyglucose F18; Male; Mice; Mice, Inbred BALB C; Positron-Emission Tomography; Radiopharmaceuticals; Tissue Distribution; Xenograft Model Antitumor Assays | 2011 |
Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft model.
Topics: Animals; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Irinotecan; Mice; Mice, SCID; Multimodal Imaging; Positron-Emission Tomography; Tomography, X-Ray Computed; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Comparison of 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Contrast Media; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Pancreatic Neoplasms; Positron-Emission Tomography; Sensitivity and Specificity; Tomography, X-Ray Computed | 2012 |
Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose- and 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography as biomarkers of therapy response in platinum-resistant ovarian cancer.
Topics: Animals; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Chlorpropamide; Dideoxynucleosides; Drug Resistance, Neoplasm; Female; Fluorodeoxyglucose F18; Humans; Ki-67 Antigen; Mice; Ovarian Neoplasms; Platinum; Positron-Emission Tomography; Time Factors; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Discriminant Analysis; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Quinazolines; Radiopharmaceuticals; Retrospective Studies; ROC Curve | 2012 |
Usefulness of FDG, MET and FLT-PET studies for the management of human gliomas.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Glioma; Humans; Linear Models; Male; Methionine; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Statistics, Nonparametric | 2012 |
High FDG and low FLT uptake in a thyroid papillary carcinoma incidentally discovered by FDG PET/CT.
Topics: Biological Transport; Carcinoma; Carcinoma, Papillary; Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Incidental Findings; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Thyroid Cancer, Papillary; Thyroid Neoplasms; Tomography, X-Ray Computed | 2012 |
Reproducibility of static and dynamic (18)F-FDG, (18)F-FLT, and (18)F-FMISO MicroPET studies in a murine model of HER2+ breast cancer.
Topics: Animals; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Kinetics; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Misonidazole; Models, Biological; Molecular Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, ErbB-2; Reproducibility of Results | 2013 |
Analysis of the growth dynamics of angiogenesis-dependent and -independent experimental glioblastomas by multimodal small-animal PET and MRI.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Data Interpretation, Statistical; Dideoxynucleosides; Disease Progression; Fluorodeoxyglucose F18; Glioblastoma; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Ki-67 Antigen; Magnetic Resonance Imaging; Methionine; Neoplasm Transplantation; Neovascularization, Pathologic; Paraffin Embedding; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Rats, Nude; Xenograft Model Antitumor Assays | 2012 |
Tumor microenvironment-dependent 18F-FDG, 18F-fluorothymidine, and 18F-misonidazole uptake: a pilot study in mouse models of human non-small cell lung cancer.
Topics: Animals; Biological Transport; Bromodeoxyuridine; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Disease Models, Animal; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mice; Misonidazole; Necrosis; Nitroimidazoles; Pilot Projects; Positron-Emission Tomography; Radioactive Tracers; Tumor Microenvironment | 2012 |
18F-FDG PET detects inflammatory infiltrates in spinal cord experimental autoimmune encephalomyelitis lesions.
Topics: Animals; Cell Proliferation; Dideoxynucleosides; Encephalomyelitis, Autoimmune, Experimental; Female; Fluorodeoxyglucose F18; Inflammation; Positron-Emission Tomography; Rats; Spinal Cord; Tyrosine | 2012 |
Usefulness of 3'-deoxy-3'-18F-fluorothymidine PET for predicting early response to chemoradiotherapy in head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Biological Transport; Carcinoma, Squamous Cell; Chemoradiotherapy; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Middle Aged; Positron-Emission Tomography; Retrospective Studies; Time Factors; Treatment Outcome | 2012 |
FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy.
Topics: Animals; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Survival; Dideoxynucleosides; Enzyme Inhibitors; Everolimus; Female; Flow Cytometry; Fluorine Radioisotopes; Fluorodeoxyglucose F18; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lymphoma, Large-Cell, Anaplastic; Mice; Mice, SCID; Positron-Emission Tomography; Protein-Tyrosine Kinases; Resorcinols; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Comparison of ( 18 ) F-FLT PET and ( 18 ) F-FDG PET for detection of cervical lymph node metastases in head and neck cancers.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Dideoxynucleosides; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Otorhinolaryngologic Neoplasms; Positron-Emission Tomography; Prospective Studies; Sensitivity and Specificity; Statistics as Topic; Tomography, X-Ray Computed | 2012 |
Intense FDG activity in a case of xanthogranulomatous cholecystitis without elevated fluorothymidine activity.
Topics: Cholecystitis; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Granuloma; Humans; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Thymidine; Tomography, X-Ray Computed; Xanthomatosis | 2013 |
[18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner.
Topics: Animals; Antibiotics, Antineoplastic; Caspase 3; Cell Proliferation; Dideoxynucleosides; Dose-Response Relationship, Drug; Doxorubicin; Female; Fluorodeoxyglucose F18; Humans; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, SCID; Neoplasm Staging; Neoplasm Transplantation; Positron-Emission Tomography; Radiopharmaceuticals; Transplantation, Heterologous | 2013 |
Single-scan dual-tracer FLT+FDG PET tumor characterization.
Topics: Brain Neoplasms; Clinical Trials as Topic; Dideoxynucleosides; Feasibility Studies; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Injections; Positron-Emission Tomography; Time Factors | 2013 |
[18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts.
Topics: Acrylamides; Animals; Antineoplastic Agents; Biological Transport; Cell Proliferation; Clinical Trials, Phase II as Topic; Dideoxynucleosides; Drug Monitoring; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gene Expression; Humans; Ki-67 Antigen; Mice; Mice, Nude; Nicotinamide Phosphoribosyltransferase; Ovarian Neoplasms; Piperidines; Positron-Emission Tomography; Radiography; Radiopharmaceuticals; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Evaluation of the antitumor effects of rilotumumab by PET imaging in a U-87 MG mouse xenograft model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biological Transport; Biomarkers; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Dose-Response Relationship, Drug; Female; Fluorodeoxyglucose F18; Glioblastoma; Hepatocyte Growth Factor; Humans; Mice; Molecular Targeted Therapy; Positron-Emission Tomography; Time Factors; Xenograft Model Antitumor Assays | 2013 |
[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice.
Topics: Animals; Antineoplastic Agents; Dideoxynucleosides; Disease Models, Animal; Female; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Humans; Hydroxamic Acids; Ki-67 Antigen; Mice; Ovarian Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Sulfonamides; Thymidine Kinase; Tumor Burden | 2013 |
18F-FLT PET/CT imaging is not competent for the pretreatment evaluation of metastatic gastric cancer: a comparison with 18F-FDG PET/CT imaging.
Topics: Adult; Aged; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Positron-Emission Tomography; Stomach Neoplasms; Tomography, X-Ray Computed; Young Adult | 2013 |
Evaluation of ¹⁸F-FDG and ¹⁸F-FLT for monitoring therapeutic responses of colorectal cancer cells to radiotherapy.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Dideoxynucleosides; Dose-Response Relationship, Radiation; Fluorodeoxyglucose F18; Humans; Metabolic Clearance Rate; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy, Image-Guided; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2013 |
Diagnostic performance of ¹⁸F-fluorothymidine PET/CT for primary colorectal cancer and its lymph node metastasis: comparison with ¹⁸F-fluorodeoxyglucose PET/CT.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2013 |
Multitracer PET imaging of bone metastases from paraganglioma: peripheral halo of uptake on 18F-FLT PET mismatching with central uptake of 18F-FDOPA, 18F-fluorodopamine, and 18F-FDG.
Topics: Adrenal Gland Neoplasms; Aged; Biological Transport; Bone Neoplasms; Dideoxynucleosides; Dihydroxyphenylalanine; Dopamine; Fluorodeoxyglucose F18; Humans; Male; Paraganglioma; Positron-Emission Tomography; Radioactive Tracers | 2013 |
Stratification of 18F-labeled PET imaging agents for the assessment of antiangiogenic therapy responses in tumors.
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Cell Line, Tumor; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Imidazoles; Indazoles; Isotope Labeling; Mice; Neoplasms, Experimental; Peptides, Cyclic; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2013 |
Heterogeneity in intratumor correlations of 18F-FDG, 18F-FLT, and 61Cu-ATSM PET in canine sinonasal tumors.
Topics: Animals; Biological Transport; Cell Hypoxia; Cell Proliferation; Coordination Complexes; Copper Radioisotopes; Dideoxynucleosides; Dog Diseases; Dogs; Fluorodeoxyglucose F18; Glucose; Neoplasm Staging; Nose Neoplasms; Organometallic Compounds; Positron-Emission Tomography; Thiosemicarbazones; Tumor Burden | 2013 |
Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901.
Topics: Animals; Aurora Kinase B; Biological Transport; Biomarkers, Tumor; Carbolines; Colorectal Neoplasms; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; HCT116 Cells; Humans; Mice; Positron-Emission Tomography; Protein Kinase Inhibitors; Sulfones; Treatment Outcome | 2014 |
A digital revolution in radiosynthesis.
Topics: Chemistry, Pharmaceutical; Dideoxynucleosides; Electrochemistry; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Microfluidic Analytical Techniques; Microfluidics; Polymers; Positron-Emission Tomography; Radiation Dosage; Radiopharmaceuticals; Technology, Pharmaceutical | 2014 |
Direct parametric image reconstruction of rapid multi-tracer PET.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Computer Simulation; Contrast Media; Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Mice; Models, Biological; Neoplasms, Experimental; Positron-Emission Tomography; Reproducibility of Results; Sensitivity and Specificity | 2013 |
Evaluation of positron emission tomographic tracers for imaging of papillomavirus-induced tumors in rabbits.
Topics: Animals; Choline; Cottontail rabbit papillomavirus; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Genome, Viral; Humans; Magnetic Resonance Spectroscopy; Neoplasms, Experimental; Papillomavirus Infections; Positron-Emission Tomography; Rabbits; Radiopharmaceuticals; Tissue Distribution | 2014 |
18F-FDG and 18F-FLT-PET imaging for monitoring everolimus effect on tumor-growth in neuroendocrine tumors: studies in human tumor xenografts in mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Drug Monitoring; Everolimus; Female; Fluorodeoxyglucose F18; Humans; Mice; Multimodal Imaging; Neuroendocrine Tumors; Positron-Emission Tomography; Tomography, X-Ray Computed; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2014 |
Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Cell Line, Tumor; Cisplatin; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Osteosarcoma; Positron-Emission Tomography; Protein Kinase Inhibitors; Sirolimus; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2014 |
Variability of Proliferation and Diffusion in Different Lung Cancer Models as Measured by 3'-Deoxy-3'-¹⁸F-Fluorothymidine PET and Diffusion-Weighted MR Imaging.
Topics: Animals; Biological Transport; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Dideoxynucleosides; Diffusion; Diffusion Magnetic Resonance Imaging; Female; Fluorodeoxyglucose F18; Humans; Kinetics; Lung Neoplasms; Mice; Positron-Emission Tomography | 2014 |
Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
Topics: Aged; Aged, 80 and over; Biological Transport; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Chemoradiotherapy; Dideoxynucleosides; Disease Progression; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Survival Analysis; Tomography, X-Ray Computed | 2014 |
PET/MR imaging and optical imaging of metastatic rhabdomyosarcoma in mice.
Topics: Animals; Dideoxynucleosides; Fluorodeoxyglucose F18; Magnetic Resonance Imaging; Mice; Positron-Emission Tomography; Radiopharmaceuticals; Rhabdomyosarcoma | 2014 |
A pilot study of the value of 18F-fluoro-deoxy-thymidine PET/CT in predicting viable lymphoma in residual 18F-FDG avid masses after completion of therapy.
Topics: Adult; Aged; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Lymphoma; Male; Middle Aged; Multimodal Imaging; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
3'-deoxy-3'-[¹⁸F]-fluorothymidine PET/CT in early determination of prognosis in patients with esophageal squamous cell cancer: comparison with [¹⁸F]-FDG PET/CT.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Dideoxynucleosides; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prognosis; ROC Curve; Tomography, X-Ray Computed; Young Adult | 2015 |
18FDG, [18F]FLT, [18F]FAZA, and 11C-methionine are suitable tracers for the diagnosis and in vivo follow-up of the efficacy of chemotherapy by miniPET in both multidrug resistant and sensitive human gynecologic tumor xenografts.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autoradiography; Carbon Radioisotopes; Cell Line, Tumor; Dideoxynucleosides; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Flow Cytometry; Fluorodeoxyglucose F18; Follow-Up Studies; Genital Neoplasms, Female; Humans; Methionine; Mice; Mice, SCID; Nitroimidazoles; Positron-Emission Tomography; Radiopharmaceuticals; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
18F-FAZA PET imaging response tracks the reoxygenation of tumors in mice upon treatment with the mitochondrial complex I inhibitor BAY 87-2243.
Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Cell Line, Tumor; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Nude; Nitroimidazoles; Oxadiazoles; Positron-Emission Tomography; Prostatic Neoplasms; Pyrazoles; Radiopharmaceuticals; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Assessment of response to neoadjuvant radiochemotherapy with F-18 FLT and F-18 FDG PET/CT in patients with rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Immunohistochemistry; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Rectal Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Prognostic value comparison between (18)F-FLT PET/CT and (18)F-FDG PET/CT volume-based metabolic parameters in patients with head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Tomography, X-Ray Computed; Tumor Burden | 2015 |
Fluorothymidine PET/CT in neurolymphomatosis.
Topics: Animals; Biopsy; Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Marek Disease; Middle Aged; Multimodal Imaging; Peripheral Nervous System Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Sciatic Neuropathy; Tomography, X-Ray Computed | 2015 |
Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Topics: Aged; Aged, 80 and over; Area Under Curve; Carcinoma, Squamous Cell; Cell Proliferation; Cohort Studies; Dideoxynucleosides; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Mouth Neoplasms; Multimodal Imaging; Neck Dissection; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; ROC Curve; Sensitivity and Specificity; Tomography, X-Ray Computed | 2015 |
Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Pilot Projects; Positron-Emission Tomography; Prospective Studies; Radiation Dosage; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model.
Topics: Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Dideoxynucleosides; Disease Models, Animal; Fluorodeoxyglucose F18; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Male; Mice; Mice, Nude; Misonidazole; Multimodal Imaging; Oligopeptides; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Tissue Distribution; Tomography, X-Ray Computed | 2015 |
Multimodal Imaging of Orthotopic Mouse Model of Endometrial Carcinoma.
Topics: Aged; Animals; Carcinoma; Cell Line, Tumor; Contrast Media; Dideoxynucleosides; Disease Models, Animal; Disease Progression; Endometrial Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Multimodal Imaging; Neoplasm Metastasis; Neoplasm Transplantation; Positron-Emission Tomography; Tomography, X-Ray Computed | 2015 |
The Synergistic Effect of Selumetinib/Docetaxel Combination Therapy Monitored by [(18)F]FDG/[(18)F]FLT PET and Diffusion-Weighted Magnetic Resonance Imaging in a Colorectal Tumor Xenograft Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Proliferation; Colorectal Neoplasms; Dideoxynucleosides; Diffusion Magnetic Resonance Imaging; Docetaxel; Drug Synergism; Fluorodeoxyglucose F18; HCT116 Cells; Humans; Immunohistochemistry; Mice; Positron-Emission Tomography; Taxoids; Xenograft Model Antitumor Assays | 2016 |
Imaging Macrophage and Hematopoietic Progenitor Proliferation in Atherosclerosis.
Topics: Animals; Aorta, Thoracic; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Bone Marrow; Carotid Artery Diseases; Cell Proliferation; Cholesterol, Dietary; Dideoxynucleosides; Diet, High-Fat; Disease Models, Animal; Female; Fluorodeoxyglucose F18; Hematopoietic Stem Cells; Humans; Macrophages; Male; Mice, Inbred C57BL; Mice, Knockout; Multimodal Imaging; Plaque, Atherosclerotic; Positron-Emission Tomography; Predictive Value of Tests; Rabbits; Radiopharmaceuticals; Retrospective Studies; Spleen; Time Factors; Tomography, X-Ray Computed | 2015 |
In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; Multimodal Imaging; Pancreatic Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Receptor, ErbB-2; Receptor, ErbB-3; Time Factors; Tumor Burden; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2015 |
ORGAN DOSES AND EFFECTIVE DOSE FOR FIVE PET RADIOPHARMACEUTICALS.
Topics: Carbon Isotopes; Choline; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Kinetics; Male; Phantoms, Imaging; Positron-Emission Tomography; Raclopride; Radiation Dosage; Radiometry; Radiopharmaceuticals; Software; Stochastic Processes; Tyrosine | 2016 |
Fibrous Dysplasia Presenting as a Cold Spot in 18F-FLT PET/CT Imaging.
Topics: Adult; Dideoxynucleosides; Fibrous Dysplasia of Bone; Fluorodeoxyglucose F18; Humans; Male; Positron Emission Tomography Computed Tomography; Pubic Bone; Radiopharmaceuticals | 2016 |
Preclinical evaluation of the anti-tumor effects of the natural isoflavone genistein in two xenograft mouse models monitored by [18F]FDG, [18F]FLT, and [64Cu]NODAGA-cetuximab small animal PET.
Topics: Acetates; Animals; Anticarcinogenic Agents; Cetuximab; Copper Radioisotopes; Dideoxynucleosides; Fluorodeoxyglucose F18; Genistein; Heterocyclic Compounds, 1-Ring; Humans; Mice; Mice, Nude; Neoplasms, Experimental; Positron-Emission Tomography; Radioisotopes; Xenograft Model Antitumor Assays | 2016 |
FLT-PET/CT diagnosis of primary and metastatic nodal lesions of gastric cancer: comparison with FDG-PET/CT.
Topics: Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Lymph Node Excision; Lymphatic Metastasis; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Stomach Neoplasms | 2016 |
A pilot study for texture analysis of
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Pilot Projects; Positron Emission Tomography Computed Tomography; Prognosis; Recurrence; Retrospective Studies; Survival Analysis | 2017 |
Myocarditis with high
Topics: Dideoxynucleosides; Electrocardiography; Fluorodeoxyglucose F18; Heart; Humans; Inflammation; Male; Myocarditis; Myocardium; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Young Adult | 2018 |
Pharmacoimaging of Blood-Brain Barrier Permeable (FDG) and Impermeable (FLT) Substrates After Intranasal (IN) Administration.
Topics: Administration, Intranasal; Animals; Blood-Brain Barrier; Dideoxynucleosides; Fluorodeoxyglucose F18; Nasal Cavity; Olfactory Bulb; Permeability; Positron-Emission Tomography; Rats; Rats, Sprague-Dawley | 2017 |
Prediction of tumor biological characteristics in different colorectal cancer liver metastasis animal models using
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Colorectal Neoplasms; Dideoxynucleosides; Feasibility Studies; Fluorodeoxyglucose F18; Humans; Hyaluronan Receptors; Immunohistochemistry; Ki-67 Antigen; Linear Models; Liver Neoplasms; Mice, Nude; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Time Factors; Vascular Endothelial Growth Factor A | 2018 |
Correlation between tumour biology status measured in triple-tracer 18F-fluorodeoxyglucose-18F-fluorothymidine- 18F-fluoromisonidazole-PET/CT study and human papillomavirus status in patients with head and neck cancer.
Topics: Aged; Aged, 80 and over; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Misonidazole; Papillomaviridae; Positron Emission Tomography Computed Tomography; Radioactive Tracers | 2019 |
[18F]fluorothymidine and [18F]fluorodeoxyglucose PET Imaging Demonstrates Uptake and Differentiates Growth in Neurofibromatosis 2 Related Vestibular Schwannoma.
Topics: Adult; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neurofibromatosis 2; Neuroma, Acoustic; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Young Adult | 2019 |
Comparing radioactive tracers 18F-FDG and 18F-FLT in the staging of diffuse large B-cell lymphoma by PET/CT examination: A single-center prospective study.
Topics: Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prospective Studies; Radioactive Tracers; Radiopharmaceuticals | 2019 |
False-Positive 18F-FDG and 18F-Fluorothymidine Uptake in a Patient With Round Atelectasis.
Topics: Biological Transport; Dideoxynucleosides; False Positive Reactions; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Pulmonary Atelectasis | 2020 |
Assessment of tumour hypoxia, proliferation and glucose metabolism in head and neck cancer before and during treatment.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Chemoradiotherapy; Cisplatin; Dideoxynucleosides; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Misonidazole; Positron Emission Tomography Computed Tomography; Prospective Studies; Radiation-Sensitizing Agents; Treatment Outcome; Tumor Hypoxia | 2020 |
Left ventricular thrombus on
Topics: Aged; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Heart Diseases; Humans; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Sarcoidosis; Thrombosis | 2021 |
Liver Abscess With High 18F-FDG Uptake and No 18F-Fluorothymidine Uptake.
Topics: Biological Transport; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Liver Abscess; Male; Middle Aged; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography | 2021 |
FLT PET/CT and FDG PET/CT of Skeletal Muscle Sarcoidosis.
Topics: Aged; Biopsy; Diagnosis, Differential; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Muscle, Skeletal; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Sarcoidosis | 2021 |
Prospective comparison of early interim
Topics: Adult; Aged; Breast Neoplasms; Combined Modality Therapy; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Middle Aged; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; ROC Curve; Treatment Outcome | 2021 |
Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Ki-67 Antigen; Mastectomy; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Estrogen; Treatment Outcome | 2021 |
PD1 blockade alters cell-cycle distribution and affects 3'-deoxy-3'-[
Topics: Animals; Cell Division; Cell Line, Tumor; Dideoxynucleosides; Disease Models, Animal; Fluorodeoxyglucose F18; Glucose; Interferons; Interleukin-2; Mice; Receptors, Death Domain; Thymidine; Tumor Necrosis Factor-alpha | 2022 |
Early Prediction of Radiotherapeutic Efficacy in a Mouse Model of Non-Small Cell Lung Carcinoma Using
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mice; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2023 |